IRON
Disc Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$78.93
+38.86%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -81.2%
- EBIT
- -59.6%
- EPS
- -47.7%
- Free cash flow
- -45.8%
- Operating cash flow
- -47.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -8.6%
- EPS
- -8.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -92.0%
- EBIT
- -81.9%
- Net income
- -94.0%
- EPS
- -51.8%
- Free cash flow
- -92.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026